Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Compare

3,986 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NTLA Analyst Ratings

Strong Buy

16 Buy

3 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NTLA Stock 12 Month Forecast

Average Price Target

$29.56

▲(145.11% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $29.56 with a high forecast of $60.00 and a low forecast of $7.00. The average price target represents a 145.11% change from the last price of $12.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","19":"$19","33":"$33","47":"$47","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,19,33,47,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,15.221538461538461,18.95307692307692,22.684615384615384,26.416153846153847,30.14769230769231,33.879230769230766,37.61076923076923,41.34230769230769,45.073846153846155,48.80538461538462,52.536923076923074,56.26846153846154,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,12.88,14.27,15.66,17.05,18.44,19.83,21.22,22.61,24,25.39,26.78,28.17,{"y":29.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,11.144615384615385,10.79923076923077,10.453846153846154,10.108461538461539,9.763076923076923,9.417692307692308,9.072307692307692,8.726923076923077,8.381538461538462,8.036153846153846,7.690769230769231,7.345384615384615,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$29.56

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Pickering

Bernstein

$14

Buy

16.09%

Upside

Reiterated

08/22/25

We rate the following companies Outperform: REGN, ALNY, BMRN, RNA, BEAM, BHVN, and NTLA.

Jonathan Miller

Evercore ISI

$48

Buy

298.01%

Upside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Debjit Chattopadhyay

Guggenheim

$45→$14

Buy

16.09%

Upside

Reiterated

08/13/25

Guggenheim Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)Guggenheim analyst Debjit Chattopadhyay lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $14.00 (from $45.00) while maintaining a Buy rating.

Mani Foroohar

Leerink Partners

$42→$41

Buy

239.97%

Upside

Reiterated

08/11/25

Intellia Therapeutics (NTLA) Receives a Buy from Leerink PartnersLeerink Partners analyst Mani Foroohar lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $41.00 (from $42.00) while maintaining a Outperform rating.

Geulah Livshits

Chardan Capital

$60

Buy

397.51%

Upside

Reiterated

08/10/25

we update our model for 2Q25 financials, Intellia's spend guidance, competitive dynamics, and the streamlined pipeline, which shift our PT to $60.

Joon Lee

Truist Financial

$33→$25

Buy

107.30%

Upside

Reiterated

08/08/25

Truist Financial Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

David Lebowitz

Citi

$10→$12

Hold

-0.50%

Downside

Reiterated

08/08/25

Citi Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Gena Wang

Barclays

$26

Buy

115.59%

Upside

Reiterated

08/08/25

Intellia Therapeutics (NTLA) Receives a Buy from Barclays

Alec Stranahan

Bank of America Securities

$39→$36

Buy

198.51%

Upside

Reiterated

08/08/25

Bank of America Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Mitchell Kapoor

H.C. Wainwright

$30→$25

Buy

107.30%

Upside

Reiterated

08/08/25

Intellia Therapeutics price target lowered to $25 from $30 at H.C. WainwrightIntellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

Whitney Ijem

Canaccord Genuity

$54

Buy

347.76%

Upside

Reiterated

08/07/25

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/07/25

Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating

Debanjana Chatterjee

JonesTrading

$25

Buy

107.30%

Upside

Reiterated

08/07/25

Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/07/25

TD Cowen Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Yanan Zhu

Wells Fargo

$50→$45

Buy

273.13%

Upside

Reiterated

08/07/25

Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Pickering

Bernstein

$14

Buy

16.09%

Upside

Reiterated

08/22/25

We rate the following companies Outperform: REGN, ALNY, BMRN, RNA, BEAM, BHVN, and NTLA.

Jonathan Miller

Evercore ISI

$48

Buy

298.01%

Upside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Debjit Chattopadhyay

Guggenheim

$45→$14

Buy

16.09%

Upside

Reiterated

08/13/25

Mani Foroohar

Leerink Partners

$42→$41

Buy

239.97%

Upside

Reiterated

08/11/25

Geulah Livshits

Chardan Capital

$60

Buy

397.51%

Upside

Reiterated

08/10/25

we update our model for 2Q25 financials, Intellia's spend guidance, competitive dynamics, and the streamlined pipeline, which shift our PT to $60.

Joon Lee

Truist Financial

$33→$25

Buy

107.30%

Upside

Reiterated

08/08/25

Truist Financial Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

David Lebowitz

Citi

$10→$12

Hold

-0.50%

Downside

Reiterated

08/08/25

Citi Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Gena Wang

Barclays

$26

Buy

115.59%

Upside

Reiterated

08/08/25

Intellia Therapeutics (NTLA) Receives a Buy from Barclays

Alec Stranahan

Bank of America Securities

$39→$36

Buy

198.51%

Upside

Reiterated

08/08/25

Bank of America Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Mitchell Kapoor

H.C. Wainwright

$30→$25

Buy

107.30%

Upside

Reiterated

08/08/25

Intellia Therapeutics price target lowered to $25 from $30 at H.C. WainwrightIntellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

Whitney Ijem

Canaccord Genuity

$54

Buy

347.76%

Upside

Reiterated

08/07/25

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/07/25

Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating

Debanjana Chatterjee

JonesTrading

$25

Buy

107.30%

Upside

Reiterated

08/07/25

Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/07/25

TD Cowen Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Yanan Zhu

Wells Fargo

$50→$45

Buy

273.13%

Upside

Reiterated

08/07/25

Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

1 Month

xxx

Success Rate

15/36 ratings generated profit

Average Return

+3.73%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +3.73% per trade.

3 Months

xxx

Success Rate

15/36 ratings generated profit

Average Return

+14.04%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +14.04% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

14/36 ratings generated profit

Average Return

+92.22%

reiterated a buy rating 28 days ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +92.22% per trade.

2 Years

xxx

Success Rate

9/26 ratings generated profit

Average Return

-29.26%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.62% of your transactions generating a profit, with an average return of -29.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTLA Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NTLA has received 21 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. NTLA average Analyst price target in the past 3 months is 29.56.

Each month's total comprises the sum of three months' worth of ratings.

NTLA Financial Forecast

NTLA Earnings Forecast

Next quarter’s earnings estimate for NTLA is -$1.01 with a range of -$1.17 to -$0.64. The previous quarter’s EPS was -$0.98. NTLA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.

NTLA Sales Forecast

Next quarter’s sales forecast for NTLA is $13.61M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $14.24M. NTLA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 29.56.

What is NTLA’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics has 145.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NTLA a Buy, Sell or Hold?

Intellia Therapeutics has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.

What is Intellia Therapeutics’s price target?

The average price target for Intellia Therapeutics is 29.56. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $7.00. The average price target represents 145.11% Increase from the current price of $12.06.

What do analysts say about Intellia Therapeutics?

Intellia Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of NTLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

NTLA Analyst Ratings

NTLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

NTLA Analyst Recommendation Trends

NTLA Financial Forecast

NTLA Earnings Forecast

NTLA Sales Forecast

NTLA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts